The increasing chronic kidney disease (CKD) prevalence threatens the health and overall quality of life. The biomarkers of the pathogenesis of CKD and the associated complications are essential for CDK diagnosis and treatment (Yiming Hao et al., 2020). Pemetrexed is a methotrexate derivative. It is authorized for advanced non-small cell lung cancer and pleural mesothelioma treatment.